 Trichomonas vaginalis is a sexually transmitted protozoan parasite that causes 156 million new cases of infection every year worldwide. It can also cause serious complications, including increased risk of developing cervical and prostate cancer when it is present without symptoms. Additionally, its presence can increase the spread of HIV, making it an important target for antiparasitic drug development. Recently, our research team discovered that the metal-based complex ceufendion was highly effective in inhibiting the activity of two key peptidases produced by T. vaginalis, which are essential for its ability to infect humans. We found that this compound interacts strongly with the active sites of both metallopeptidase TVMP50 and GP63, which are involved in the parasite's ability to cause disease. Furthermore, ceufendion was able to reduce the cytotoxicity of T. vaginalis in human vaginal and monkey kidney cells, suggesting that it could be used as a potential treatment for trichomoniasis. This article was authored by Grisela Vargas-Rigo, Fernanda Gomez Cardoso, Mateus Mendoza-Parrera, and others. We are article.tv, links in the description below.